{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T18:58:23Z","timestamp":1776452303804,"version":"3.51.2"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s12325-019-00907-8","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T10:02:54Z","timestamp":1553162574000},"page":"1031-1051","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist"],"prefix":"10.1007","volume":"36","author":[{"given":"Dhiren","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis","family":"Triplitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Trujillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"key":"907_CR1","unstructured":"World Health Organization. Global report on diabetes. 2016. http:\/\/apps.who.int\/iris\/bitstream\/10665\/204871\/1\/9789241565257_eng.pdf?ua=1 . Accessed 23 July 2018."},{"key":"907_CR2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","volume":"55","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577\u201396.","journal-title":"Diabetologia"},{"key":"907_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2012.10.001","volume":"104","author":"International Diabetes Federation Guideline Development Group","year":"2014","unstructured":"International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014;104:1\u201352.","journal-title":"Diabetes Res Clin Pract"},{"key":"907_CR4","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","volume":"61","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61:2461\u201398.","journal-title":"Diabetologia"},{"key":"907_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4158\/CS-2017-0153","volume":"24","author":"AJ Garber","year":"2018","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142018 executive summary. Endoc Practice. 2018;24:91\u2013120.","journal-title":"Endoc Practice"},{"issue":"Suppl 1","key":"907_CR6","first-page":"S1","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142018. Diabetes Care. 2018;41(Suppl 1):S1\u2013159.","journal-title":"Diabetes Care"},{"key":"907_CR7","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2337\/dc12-2258","volume":"36","author":"S Stark Casagrande","year":"2013","unstructured":"Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988\u20132010. Diabetes Care. 2013;36:2271\u20139.","journal-title":"Diabetes Care"},{"key":"907_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s13300-014-0077-8","volume":"5","author":"WD Strain","year":"2014","unstructured":"Strain WD, Bl\u00fcher M, Pald\u00e1nius P. Clinical inertia in individualising care for diabetes: is there time to do more in type 2 diabetes? Diabetes Ther. 2014;5:347\u201354.","journal-title":"Diabetes Ther"},{"key":"907_CR9","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.2337\/dc13-0331","volume":"36","author":"K Khunti","year":"2013","unstructured":"Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411\u20137.","journal-title":"Diabetes Care"},{"key":"907_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/dom.12626","volume":"18","author":"K Khunti","year":"2016","unstructured":"Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18:401\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"907_CR11","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","volume":"29","author":"M Peyrot","year":"2012","unstructured":"Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29:682\u20139.","journal-title":"Diabet Med"},{"key":"907_CR12","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.2337\/diacare.28.11.2673","volume":"28","author":"M Peyrot","year":"2005","unstructured":"Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673\u20139.","journal-title":"Diabetes Care"},{"key":"907_CR13","unstructured":"Ide L. Expanding pharmacist provider status can improve diabetes management. 2015. https:\/\/www.ajmc.com\/contributor\/lucienne-ide-md-phd\/2015\/12\/expanding-pharmacist-provider-status-can-improve-diabetes-management . Accessed 23 July 2018."},{"key":"907_CR14","unstructured":"Shane-McWhorter L. The scope and standards for the practice of diabetes education by pharmacists. American Association of Diabetes Educators. https:\/\/www.diabeteseducator.org\/docs\/default-source\/legacy-docs\/_resources\/pdf\/PharmDScopeStandards.pdf . Accessed 23 July 2018."},{"key":"907_CR15","first-page":"CD011227","volume":"11","author":"G Weeks","year":"2016","unstructured":"Weeks G, George J, Maclure K, Stewart D. Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care. Cochrane Datab Syst Rev. 2016;11:CD011227.","journal-title":"Cochrane Datab Syst Rev"},{"key":"907_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.diabres.2010.09.023","volume":"92","author":"C Collins","year":"2011","unstructured":"Collins C, Limone BL, Scholle JM, Coleman CI. Effect of pharmacist intervention on glycemic control in diabetes. Diabet Res Clin Pract. 2011;92:145\u201352.","journal-title":"Diabet Res Clin Pract"},{"key":"907_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1592\/phco.26.2.248","volume":"26","author":"AD McCord","year":"2006","unstructured":"McCord AD. Clinical impact of a pharmacist-managed diabetes mellitus drug therapy management service. Pharmacotherapy. 2006;26:248\u201353.","journal-title":"Pharmacotherapy"},{"key":"907_CR18","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2146\/ajhp050430","volume":"63","author":"CM Morello","year":"2006","unstructured":"Morello CM, Zadvorny EB, Cording MA, Suemoto RT, Skog J, Harari A. Development and clinical outcomes of pharmacist-managed diabetes care clinics. Am J Health Syst Pharm. 2006;63:1325\u201331.","journal-title":"Am J Health Syst Pharm"},{"key":"907_CR19","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/j.1365-2710.2010.01218.x","volume":"36","author":"E Mehuys","year":"2011","unstructured":"Mehuys E, Van Bortel L, De Bolle L, et al. Effectiveness of a community pharmacist intervention in diabetes care: a randomized controlled trial. J Clin Pharm Ther. 2011;36:602\u201313.","journal-title":"J Clin Pharm Ther"},{"key":"907_CR20","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2146\/ajhp150778","volume":"73","author":"H Ourth","year":"2016","unstructured":"Ourth H, Groppi J, Morreale AP, Quicci-Roberts K. Clinical pharmacist prescribing activities in the Veterans Health Administration. Am J Health Syst Pharm. 2016;73:1406\u201315.","journal-title":"Am J Health Syst Pharm"},{"key":"907_CR21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1177\/1060028016663564","volume":"50","author":"J Sullivan","year":"2016","unstructured":"Sullivan J, Jett BP, Cradick M, Zuber J. Effect of clinical pharmacist intervention on A1C reduction in veteran patients with type 2 diabetes in a rural setting. Ann Pharmacother. 2016;50:1023\u20137.","journal-title":"Ann Pharmacother"},{"key":"907_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/phar.1719","volume":"36","author":"LG Maxwell","year":"2016","unstructured":"Maxwell LG, McFarland MS, Baker JW, Cassidy RF. Evaluation of the impact of a pharmacist-led telehealth clinic on diabetes-related goals of therapy in a veteran population. Pharmacotherapy. 2016;36:348\u201356.","journal-title":"Pharmacotherapy"},{"key":"907_CR23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/1060028017733272","volume":"52","author":"MA Deters","year":"2018","unstructured":"Deters MA, Laven A, Castejon A, et al. Effective interventions for diabetes patients by community pharmacists: a meta-analysis of pharmaceutical care components. Ann Pharmcother. 2018;52:198\u2013211.","journal-title":"Ann Pharmcother"},{"key":"907_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1345\/aph.1Q512","volume":"46","author":"MC Salvo","year":"2012","unstructured":"Salvo MC, Brooks AM. Glycemic control and preventive care measures of indigent diabetes patients within a pharmacist-managed insulin titration program vs standard care. Ann Pharmacother. 2012;46:29\u201334.","journal-title":"Ann Pharmacother"},{"key":"907_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2146\/ajhp080706","volume":"67","author":"CD Rochester","year":"2010","unstructured":"Rochester CD, Leon N, Dombrowski R, Haines ST. Collaborative drug therapy management for initiating and adjusting insulin therapy in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2010;67:42\u20138.","journal-title":"Am J Health Syst Pharm"},{"key":"907_CR26","doi-asserted-by":"publisher","first-page":"e003154","DOI":"10.1136\/bmjopen-2013-003154","volume":"3","author":"YN Al Hamarneh","year":"2013","unstructured":"Al Hamarneh YN, Charrois T, Lewanczuk R, Tsuyuki RT. Pharmacist intervention for glycaemic control in the community (the RxING study). BMJ Open. 2013;3:e003154.","journal-title":"BMJ Open"},{"key":"907_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2337\/diaspect.24.4.211","volume":"24","author":"JM Pitlick","year":"2011","unstructured":"Pitlick JM, Brooks AD. Glycemic control in pharmacist-managed insulin titration versus standard care in an indigent population. Diabetes Spectrum. 2011;24:211\u20137.","journal-title":"Diabetes Spectrum"},{"issue":"52","key":"907_CR28","first-page":"e266","volume":"2012","author":"E Weidman-Evans","year":"2003","unstructured":"Weidman-Evans E, Evans J, Eastwood R, Fort A. Implementation of a pharmacist-run telephonic insulin titration service. J Am Pharm Assoc. 2003;2012(52):e266\u201372.","journal-title":"J Am Pharm Assoc"},{"key":"907_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1042-0991(15)30967-1","volume":"20","author":"American Pharmacists Association","year":"2014","unstructured":"American Pharmacists Association. Understanding insulin management: role of the pharmacist. Pharmacy Today. 2014;20:85\u201396.","journal-title":"Pharmacy Today."},{"key":"907_CR30","unstructured":"Lantus. US prescribing information (PI). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021081s034lbl.pdf . Accessed 23 July 2018."},{"key":"907_CR31","unstructured":"Basaglar. US prescribing information (PI). http:\/\/uspl.lilly.com\/basaglar\/basaglar.html#pi . Accessed 4 Mar 2019."},{"key":"907_CR32","unstructured":"Toujeo. US prescribing information (PI). http:\/\/products.sanofi.us\/toujeo\/toujeo.pdf . Accessed 30 Aug 2018."},{"key":"907_CR33","unstructured":"Tresiba. US prescribing information (PI). https:\/\/www.novo-pi.com\/tresiba.pdf . Accessed 4 Mar 2019."},{"key":"907_CR34","unstructured":"Levemir. US prescribing information (PI). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021536s037lbl.pdf . Accessed 23 July 2018."},{"key":"907_CR35","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1463-1326.2007.00756.x","volume":"9","author":"T Heise","year":"2007","unstructured":"Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9:648\u201359.","journal-title":"Diabetes Obes Metab"},{"key":"907_CR36","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/S0140-6736(98)12459-5","volume":"354","author":"PM Jehle","year":"1999","unstructured":"Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet. 1999;354:1604\u20137.","journal-title":"Lancet"},{"key":"907_CR37","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/193229681200600229","volume":"6","author":"S Reutrakul","year":"2012","unstructured":"Reutrakul S, Wroblewski K, Brown RL. Clinical use of U-500 regular insulin: review and meta-analysis. J Diabetes Sci Technol. 2012;6:412\u201320.","journal-title":"J Diabetes Sci Technol"},{"issue":"5 Suppl 1","key":"907_CR38","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.3949\/ccjm.83.s1.05","volume":"83","author":"L Meneghini","year":"2016","unstructured":"Meneghini L. New insulin preparations: a primer for the clinician. Cleve Clin J Med. 2016;83(5 Suppl 1):S27\u201333.","journal-title":"Cleve Clin J Med"},{"key":"907_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/ijcp.12747","volume":"70","author":"T Reid","year":"2016","unstructured":"Reid T, Reid T, Gao L, et al. How much is too much? Outcomes in patients using high-dose insulin glargine. Int J Clin Pract. 2016;70:56\u201365.","journal-title":"Int J Clin Pract"},{"key":"907_CR40","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/ijcp.12337","volume":"68","author":"P Rys","year":"2014","unstructured":"Rys P, Wojciechowski P, Siejka S, Ma\u0142ecki P, Hak \u0141, Malecki MT. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus\u2014a systematic review and meta-analysis. Int J Clin Pract. 2014;68:304\u201313.","journal-title":"Int J Clin Pract"},{"key":"907_CR41","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jdiacomp.2015.04.003","volume":"29","author":"P Aschner","year":"2015","unstructured":"Aschner P, Sethi B, Gomez-Peralta F, et al. Insulin glargine compared with premixed insulin for management of insulin-na\u00efve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study. J Diabetes Complications. 2015;29:838\u201345.","journal-title":"J Diabetes Complications"},{"key":"907_CR42","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","volume":"26","author":"MC Riddle","year":"2003","unstructured":"Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080\u20136.","journal-title":"Diabetes Care"},{"key":"907_CR43","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.clinthera.2006.10.020","volume":"28","author":"A Philis-Tsimikas","year":"2006","unstructured":"Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28:1569\u201381.","journal-title":"Clin Ther"},{"key":"907_CR44","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.2337\/diabetes.53.6.1614","volume":"53","author":"T Heise","year":"2004","unstructured":"Heise T, Nosek L, R\u00f8nn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614\u201320.","journal-title":"Diabetes"},{"key":"907_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3121\/cmr.2008.793","volume":"6","author":"I Hartman","year":"2008","unstructured":"Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res. 2008;6:54\u201367.","journal-title":"Clin Med Res"},{"key":"907_CR46","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/dom.12482","volume":"17","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus) in patients with type 2 diabetes who were insulin-na\u00efve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17:734\u201341.","journal-title":"Diabetes Obes Metab"},{"key":"907_CR47","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/dom.12628","volume":"18","author":"I Hadjiyianni","year":"2016","unstructured":"Hadjiyianni I, Dahl D, Lacaya LB, Pollom RK, Chang CL, Ilag LL. Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine. Diabetes Obes Metab. 2016;18:425\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"907_CR48","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2337\/diacare.28.5.1107","volume":"28","author":"J Plank","year":"2005","unstructured":"Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107\u201312.","journal-title":"Diabetes Care"},{"key":"907_CR49","first-page":"CD006383","volume":"7","author":"SG Swinnen","year":"2011","unstructured":"Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;7:CD006383.","journal-title":"Cochrane Database Syst Rev"},{"key":"907_CR50","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.2337\/dc05-1365","volume":"29","author":"K Hermansen","year":"2006","unstructured":"Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269\u201374.","journal-title":"Diabetes Care"},{"key":"907_CR51","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2337\/dc14-0006","volume":"38","author":"RH Becker","year":"2015","unstructured":"Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300\u00a0units\u00a0mL\u22121 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100\u00a0units\u00a0mL\u22121. Diabetes Care. 2015;38:637\u201343.","journal-title":"Diabetes Care"},{"key":"907_CR52","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/dme.13002","volume":"33","author":"S Heller","year":"2016","unstructured":"Heller S, Mathieu C, Kapur R, Wolden ML, Zinman B. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia. Diabet Med. 2016;33:478\u201387.","journal-title":"Diabet Med"},{"key":"907_CR53","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S2213-8587(13)70013-5","volume":"1","author":"B Zinman","year":"2013","unstructured":"Zinman B, DeVries JH, Bode B, et al. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26\u00a0weeks, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes Endocrinol. 2013;1:123\u201331.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"907_CR54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.diabet.2017.10.001","volume":"44","author":"TS Bailey","year":"2018","unstructured":"Bailey TS, Pettus B, Roussel R, et al. Morning administration of 0.4\u00a0U\/kg\/day insulin glargine 300\u00a0U\/mL provides less fluctuating 24-h pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100\u00a0U\/mL in type 1 diabetes. Diabetes Metab. 2018;44:15\u201321.","journal-title":"Diabetes Metab"},{"key":"907_CR55","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/dom.12438","volume":"17","author":"GB Bolli","year":"2015","unstructured":"Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300\u00a0U\/ml compared with glargine 100\u00a0U\/ml in insulin-na\u00efve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17:386\u201394.","journal-title":"Diabetes Obes Metab"},{"key":"907_CR56","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/dom.12485","volume":"17","author":"R Ritzel","year":"2015","unstructured":"Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300\u00a0U\/ml versus glargine 100\u00a0U\/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17:859\u201367.","journal-title":"Diabetes Obes Metab"},{"key":"907_CR57","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1463-1326.2012.01638.x","volume":"14","author":"T Heise","year":"2012","unstructured":"Heise T, Nosek L, B\u00f8ttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944\u201350.","journal-title":"Diabetes Obes Metab"},{"key":"907_CR58","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40262-014-0165-y","volume":"53","author":"H Haahr","year":"2014","unstructured":"Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53:787\u2013800.","journal-title":"Clin Pharmacokinet"},{"key":"907_CR59","first-page":"483","volume":"8","author":"P Thuillier","year":"2015","unstructured":"Thuillier P, Alavi Z, Kerlan V. Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes. Diabetes Metab Syndr Obes. 2015;8:483\u201393.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"907_CR60","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40261-013-0096-7","volume":"33","author":"S Korsatko","year":"2013","unstructured":"Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200\u00a0U\/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig. 2013;33:515\u201321.","journal-title":"Clin Drug Investig"},{"key":"907_CR61","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.2337\/dc12-1205","volume":"35","author":"B Zinman","year":"2012","unstructured":"Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35:2464\u201371.","journal-title":"Diabetes Care"},{"key":"907_CR62","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.2337\/dc12-2329","volume":"36","author":"SC Gough","year":"2013","unstructured":"Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 units\/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-na\u00efve patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36:2536\u201342.","journal-title":"Diabetes Care"},{"key":"907_CR63","doi-asserted-by":"publisher","first-page":"858","DOI":"10.2337\/dc12-1668","volume":"36","author":"L Meneghini","year":"2013","unstructured":"Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36:858\u201364.","journal-title":"Diabetes Care"},{"key":"907_CR64","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/jdi.12102","volume":"4","author":"Y Onishi","year":"2013","unstructured":"Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin-na\u00efve patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig. 2013;4:605\u201312.","journal-title":"J Diabetes Investig"},{"key":"907_CR65","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jama.2017.7117","volume":"318","author":"C Wysham","year":"2017","unstructured":"Wysham C, Bhargava A, Chaykin L, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017;318:45\u201356.","journal-title":"JAMA"},{"key":"907_CR66","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","volume":"49","author":"H Yki-J\u00e4rvinen","year":"2006","unstructured":"Yki-J\u00e4rvinen H, Kauppinen-M\u00e4kelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442\u201351.","journal-title":"Diabetologia"},{"key":"907_CR67","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00125-007-0911-x","volume":"51","author":"J Rosenstock","year":"2008","unstructured":"Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-na\u00efve people with type 2 diabetes. Diabetologia. 2008;51:408\u201316.","journal-title":"Diabetologia"},{"key":"907_CR68","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/dom.12083","volume":"15","author":"L Meneghini","year":"2013","unstructured":"Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:729\u201336.","journal-title":"Diabetes Obes Metab"},{"key":"907_CR69","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.2337\/diacare.28.6.1282","volume":"28","author":"M Davies","year":"2005","unstructured":"Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282\u20138.","journal-title":"Diabetes Care"},{"key":"907_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/diacare.29.01.06.dc05-1058","volume":"29","author":"L Kennedy","year":"2006","unstructured":"Kennedy L, Herman WH, Strange P, Harris A. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care. 2006;29:1\u20138.","journal-title":"Diabetes Care"},{"key":"907_CR71","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/j.1463-1326.2007.00804.x","volume":"9","author":"L Meneghini","year":"2007","unstructured":"Meneghini L, Koenen C, Weng W, Selam JL. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes\u2014results of the randomized, controlled PREDICTIVE\u2122 303 study. Diabetes Obes Metab. 2007;9:902\u201313.","journal-title":"Diabetes Obes Metab"},{"key":"907_CR72","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1463-1326.2009.01060.x","volume":"11","author":"L Blonde","year":"2009","unstructured":"Blonde L, Merilainen M, Karwe V, Raskin P. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets\u2014the TITRATE study. Diabetes Obes Metab. 2009;11:623\u201331.","journal-title":"Diabetes Obes Metab"},{"key":"907_CR73","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12325-013-0036-1","volume":"30","author":"A Philis-Tsimikas","year":"2013","unstructured":"Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J. Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use). Adv Ther. 2013;30:607\u201322.","journal-title":"Adv Ther"},{"key":"907_CR74","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/1753-0407.12080","volume":"6","author":"G Dailey","year":"2014","unstructured":"Dailey G, Aurand L, Stewart J, Ameer B, Zhou R. Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naive patients with type 2 diabetes mellitus. J Diabetes. 2014;6:176\u201383.","journal-title":"J Diabetes"},{"key":"907_CR75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/dom.12329","volume":"17","author":"PD Home","year":"2015","unstructured":"Home PD, Bolli GB, Mathieu C, et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-na\u00efve people with type 2 diabetes. Diabetes Obes Metab. 2015;17:15\u201322.","journal-title":"Diabetes Obes Metab"},{"key":"907_CR76","unstructured":"Yale J-F, Harris SB, Berard L, Groleau M, JavadiP, Stewart J. Safety and efficacy of a pragmatic self-titration 1 unit\/day (INSIGHT) algorithm for insulin glargine 300 U\/mL (Gla-300). Poster presented at the 52nd European Association for the Study of Diabetes (EASD) annual meeting; September 12\u201316, 2016; Munich, Germany. https:\/\/www.easd.org\/virtualmeeting\/home.html#!resources\/safety-and-efficacy-of-a-pragmatic-self-titration-1-unit-day-insight-algorithm-for-insulin-glargine-300-u-ml-gla-300-d617e461-efcf-4b97-b66f-f0d3171bb987 . Accessed 23 July 2018."},{"key":"907_CR77","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2337\/diacare.22.3.394","volume":"22","author":"RL Ollerton","year":"1999","unstructured":"Ollerton RL, Playle R, Ahmed K, Dunstan FD, Luzio SD, Owens DR. Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care. 1999;22:394\u20138.","journal-title":"Diabetes Care"},{"key":"907_CR78","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1177\/1932296815586425","volume":"9","author":"AB King","year":"2015","unstructured":"King AB. Misled by the morning \u201cfasting\u201d plasma glucose. J Diabetes Sci Technol. 2015;9:1342\u20135.","journal-title":"J Diabetes Sci Technol"},{"key":"907_CR79","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.2337\/dc18-0559","volume":"4","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Cheng A, Ritzel R, et al. More similarities than differences testing insulin glargine 300\u00a0units\/mL versus insulin degludec \u00a0units\/mL in insulin-naive type 2 diabetes: the Randomized Head-to-Head BRIGHT Trial. Diabetes Care. 2018;4:2147\u201354.","journal-title":"Diabetes Care"},{"key":"907_CR80","unstructured":"FDA. Department of Health and Human Services Section review of 510(k). 2016. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf16\/K161433.pdf . Accessed 23 July 2018."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00907-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-00907-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00907-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T03:37:20Z","timestamp":1663126640000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-00907-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["907"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-00907-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,21]]},"assertion":[{"value":"18 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}